More cases of paroxetine withdrawal syndrome
Open accessAbstract
Yobimbine and sinusitis
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The authors of the fluoxetine case reports did not report information on the duration of the withdrawal syndromes, probably because symptoms were treated by reintroducing fluoxetine or administering other drugs.
“The authors did not report information on the duration of the withdrawal syndromes, probably because symptoms were treated reintroducing fluoxetine [10,57,58] or administering other drugs [1,5] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [5]
The Abstract (page unavailable) explicitly reports that withdrawal symptoms persisted for approximately seven days in all five cases, contrary to the claim that duration was not reported. It also says two patients received lorazepam, but these were paroxetine—not fluoxetine—withdrawal cases. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Physical symptoms associated with paroxetine discontinuation
Barr, L. C., Goodman, W. K., & Price, L. H. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.2.289 · Cited by 72 · see citing works
Paroxetine withdrawal syndrome
Pyke, R. E. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.149b · Cited by 31 · see citing works
Fluoxetine withdrawal symptoms.
Berlin, C. S. (1996) · PubMed · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 421 · see citing works
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207 · see citing works
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · see citing works
Goldstein, B. J., & Goodnick, P. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003041 · Cited by 171 · see citing works
The SSRI discontinuation syndrome
Haddad, P. M. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200311 · Cited by 123 · see citing works
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109 · see citing works
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment
Judge, R., Parry, M. G., Quail, D., & Jacobson, J. G. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00002 · Cited by 87 · see citing works
Bogetto, F., Bellino, S., Revello, R. B., & Patria, L. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00006 · Cited by 80 · see citing works
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76 · see citing works
Martin, R. M., May, M., & Gunnell, D. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02527.x · Cited by 51 · see citing works
Quilichini, J.-B., Revet, A., Garcia, P., Bouquié, R., Hamard, J., Yrondi, A., & Montastruc, F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.041 · Cited by 39 · see citing works
Long Term Treatment of Obsessive-Compulsive Disorder
Ravizza, L., Maina, G., Bogetto, F., Albert, U., Barzega, G., & Bellino, S. (1998) · CNS Drugs · doi:10.2165/00023210-199810040-00003 · Cited by 18 · see citing works
Antidepressant withdrawal syndrome
Young, A. H., Currie, A., & Ashton, C. H. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.3.288a · Cited by 17 · see citing works
Discontinuation Symptoms with Nefazodone
Rajagopalan, M., & Little, J. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.1999.00567.x · Cited by 11 · see citing works
Rivas-Vazquez, R. A., Johnson, S. L., Blais, M. A., & Rey, G. J. F. D. (1999) · Professional Psychology Research and Practice · doi:10.1037/0735-7028.30.5.464 · Cited by 8 · see citing works
New Dosage-Reduction Regime to Avoid Paroxetine Discontinuation Syndrome
Yáñez, L. P., Malo, P., Etxebeste, M. A., de Zárate, E. A. O., & Medrano, J. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800217 · Cited by 1 · see citing works
Self-citation&NA; (1996) · Reactions Weekly · doi:10.2165/00128415-199606290-00027
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature
Therrien, F., & Markowitz, J. S. (1997) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/(sici)1099-1077(199707/08)12:4
Nemeroff (1998) · doi:10.1002/(sici)1520-6394(1998)8:1+
- Authors
- Pacheco, L., Malo, P., Aragues, E., & Etxebeste, M.
- Affiliations
- Basque Government (ES)
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1996-09
- Volume
- 169
- Issue
- 3
- Pages
- 384-384
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2104826183
- Cited by
- 21
- References
- 3
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 1 · 2015: 1
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The British Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- paroxetine, withdrawal syndrome, selective serotonin reuptake inhibitors, antidepressant discontinuation, sinusitis
- MeSH terms
- Adult, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Neurologic Examination, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
